Significant event | Non-significant event | P values | |
N | 86 | 249 | |
Demographics | |||
Age, years | 54±17 | 49±16 | 0.03 |
Sex, female n (%) | 51 (59) | 145 (58) | 0.86 |
Ethnicity, Chinese n (%) | 72 (84) | 203 (82) | 0.90 |
BMI, kg/m2 | 24.2±4.3 | 24.1±5.0 | 0.96 |
Clinical covariates | |||
Palpitations n (%) | 81 (96) | 222 (93) | 0.21 |
Dizziness n (%) | 19 (24) | 60 (26) | 0.67 |
Family history of SCD n (%) | 2 (3) | 2 (1) | 0.28 |
Known AF n (%) | 12 (14) | 6 (2) | <0.001 |
Other arrhythmias n (%) | 22 (27) | 21 (8) | <0.001 |
Previous Holter n (%) | 34 (40) | 67 (27) | 0.03 |
Previous abnormal Holter n (%) | 21 (24) | 15 (6) | <0.001 |
Previous ablation n (%) | 4 (5) | 8 (3) | 0.55 |
Echocardiographic EF n (%) | 63±4 | 63±6 | 0.90 |
ECG parameters | |||
PR, ms | 167±42 | 160±24 | 0.045 |
QRS, ms | 92±17 | 91±14 | 0.58 |
QTc, ms | 432±29 | 433±24 | 0.76 |
Axis, degrees | 44±32 | 42±40 | 0.66 |
Sinus rhythm n (%) | 79 (98) | 237 (98) | 0.86 |
LVH n (%) | 3 (4) | 20 (9) | 0.14 |
BBB n (%) | 0.28 | ||
Right | 5 (6) | 6 (3) | |
Left | 0 (0) | 1 (0.4) | |
Medications | |||
Beta-blocker n (%) | 38 (44) | 68 (27) | <0.01 |
Non-dihydropyridine CCB n (%) | 3 (4) | 7 (3) | 0.76 |
Digoxin n (%) | 1 (1) | 0 (0) | NA |
Other antiarrhythmics n (%) | 2 (2) | 2 (1) | NA |
Duration of monitoring | 0.13 | ||
1 Week n (%) | 1 (1) | 20 (8) | |
2 Weeks n (%) | 80 (93) | 210 (84) | |
3 Weeks n (%) | 5 (6) | 19 (8) | |
4 Weeks n (%) | 0 (0) | 1 (0.4) |
Comparison of baseline characteristics of patients with and without detected clinically significant events.
AF, atrial fibrillation; NA, not available.